Logotype for ICU Medical Inc

ICU Medical (ICUI) Q4 2018 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for ICU Medical Inc

Q4 2018 earnings summary

6 Nov, 2026

Executive summary

  • 2018 integration of Hospira Infusion Systems reached its final stages: unified commercial, manufacturing, supply-chain and IT platforms, with Pfizer transition services exited.

  • Profitability and cash generation improved; adjusted EBITDA was nearly $290M, and year-end cash and short-term investments were $382.1M with no borrowings.

  • Reported net income declined to $28.8M from $68.6M in 2017, amid $105.4M of restructuring and integration costs, a $41.6M contract settlement charge and a $20.4M earn-out fair-value charge.

Financial highlights

  • FY 2018 revenue was $1.400B; gross profit was $570.0M, operating income $21.6M, and net income $28.8M.

  • Operating cash flow was $160.2M versus $154.4M in 2017; cash, cash equivalents and short-term investments increased to $382.1M from $300.1M.

  • Q4 revenue was $340.4M; gross profit $134.6M; net loss $7.4M and diluted loss per share $0.36.

  • Q4 net loss included $41.1M in restructuring, strategic transaction and integration expenses; an additional $8.6M non-cash contract-settlement charge was recorded in the quarter.

  • ASC 606 adoption increased FY revenue by $11.1M and gross profit by $7.7M versus the prior standard; opening retained earnings rose $6.3M.

Outlook and guidance

  • FY 2019 capital expenditures were estimated at $95M–$105M, directed to manufacturing capacity, customer-placed infusion products and IT; cash and operating cash flow were expected to fund these investments.

  • 2019 was expected to have a difficult first-half comparison due to IV Solutions shortages continuing into early 2018; integration cash costs were expected to continue at a much lower level.

  • Focus areas included segment positioning, operating stability after integration, R&D and longer-term capital deployment; product launches were expected to broaden offerings over the medium term.

  • Existing cash and expected operating cash flow were considered sufficient for operations over the next 12 months; no certainty was given for longer-term funding needs.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from ICU Medical